Biophytis SA (BPTS): Price and Financial Metrics

Biophytis SA (BPTS): $8.22

1.48 (-15.26%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

F

Add BPTS to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#255 of 489

in industry

BPTS Price/Volume Stats

Current price $8.22 52-week high $168.80
Prev. close $9.70 52-week low $8.05
Day low $8.05 Volume 18,500
Day high $8.96 Avg. volume 7,291
50-day MA $16.22 Dividend yield N/A
200-day MA $35.36 Market Cap 2.89M

BPTS Stock Price Chart Interactive Chart >


Biophytis SA (BPTS) Company Bio


Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France.


BPTS Latest News Stream


Event/Time News Detail
Loading, please wait...

BPTS Latest Social Stream


Loading social stream, please wait...

View Full BPTS Social Stream

BPTS Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -73.89%
3-year -99.60%
5-year N/A
YTD -69.36%
2023 -83.02%
2022 -92.60%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!